Sotera Health (NASDAQ:SHC) Releases FY 2024 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 0.670-0.750 for the period, compared to the consensus EPS estimate of 0.720. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Sotera Health also updated its FY24 guidance to $0.67-0.75 EPS.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SHC. Citigroup lifted their target price on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays upped their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Sotera Health Stock Performance

SHC opened at $15.77 on Friday. The firm has a market cap of $4.47 billion, a P/E ratio of 63.32 and a beta of 2.08. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.59 and a current ratio of 2.88. The business’s fifty day moving average is $15.96 and its 200-day moving average is $13.69.

Sotera Health (NASDAQ:SHC) last released its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Sell-side analysts expect that Sotera Health will post 0.64 EPS for the current fiscal year.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 55.12% of the stock is currently owned by insiders.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.